Abstract:The etiology of Parkinson's disease (PD) is characterized by the death of dopamine neurons in the substantia nigra pars compacta, while misfolding and abnormal aggregation of α-synuclein (α-syn) are core pathological features. Previous studies have suggested that damage to dopamine neurons may be related to cell cycle dysregulation, but the specific mechanisms remain unclear. In this study, a PD mouse model was induced by stereotactic injection of α-syn into the nucleus, and treated with the cell cycle inhibitor, roscovitine (Rosc). The results demonstrated that Rosc improved behavioral disorders caused by α-syn, increased TH protein expression, inhibited α-syn and p-α-syn protein expression, and reduced the expression levels of G1/S phase cell cycle genes Cyclin D1, Cyclin E, CDK2, CDK4, E2F and pRB. Additionally, Rosc decreased Bax and Caspase-3 expression caused by α-syn, while increasing Bcl-2 protein expression. Meanwhile, we observed that α-syn can influence neuronal cell autophagy by decreasing the expression level of Beclin 1 and increasing the expression level of P62. However, Rosc can improve this phenomenon. In a cell model induced by α-syn in dopamine neuron injury cells, knockdown of Cyclin D1 led to similar results as those observed in animal experiments: Knocking down Cyclin D1 improved the abnormal initiation of the cell cycle caused by α-syn and regulated cellular autophagy, resulting in a reduction of apoptosis in dopamine neurons. In summary, exogenous α-syn can lead to the accumulation of α-syn and phosphorylated α-syn in dopamine neurons, increase key factors of the G1/S phase cell cycle such as Cyclin D1, and regulate downstream related indicators, causing the cell cycle to restart and leading to apoptosis of dopamine neurons. This exacerbates PD symptoms. However, knockdown of Cyclin D1 inhibits the progression of the cell cycle and can reverse this situation. These findings suggest that a Cyclin D inhibitor may be a novel therapeutic target for treating PD.

Α-Synuclein Induces Deficiency in Clathrin-Mediated Endocytosis Through Inhibiting Synaptojanin1 Expression

Synj1 Haploinsufficiency Causes Dopamine Neuron Vulnerability and Alpha-Synuclein Accumulation in Mice

Estrogen-related receptor gamma regulates mitochondrial and synaptic genes and modulates vulnerability to synucleinopathy

Synuclein Impairs Trafficking and Signaling of BDNF in a Mouse Model of Parkinson’s Disease

Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity

Α‐synuclein Stimulation of Monoamine Oxidase‐b and Legumain Protease Mediates the Pathology of Parkinson's Disease

Nutrient Deprivation Induces Α-Synuclein Aggregation Through Endoplasmic Reticulum Stress Response and SREBP2 Pathway.

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease

Conditional Expression Of Parkinson'S Disease-Related Mutant Alpha-Synuclein In The Midbrain Dopaminergic Neurons Causes Progressive Neurodegeneration And Degradation Of Transcription Factor Nuclear Receptor Related 1

Synaptojanin1 Modifies Endolysosomal Parameters in Cultured Ventral Midbrain Neurons

Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy

Altered Conformation of Α-Synuclein Drives Dysfunction of Synaptic Vesicles in a Synaptosomal Model of Parkinson's Disease.

Asparagine endopeptidase cleaves synaptojanin 1 and triggers synaptic dysfunction in Parkinson's disease

α-Synuclein promotes clathrin-mediated NMDA receptor endocytosis and attenuates NMDA-induced dopaminergic cell death.

Alpha-synuclein Promotes Clathrin-Mediated Endocytosis of NMDA Receptors in Dopaminergic Cells

A Calcineurin- and NFAT-dependent Pathway is Involved in Α-Synuclein-induced Degeneration of Midbrain Dopaminergic Neurons.

Alteration of dynein function affects α-synuclein degradation via the autophagosome-lysosome pathway.

Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2

alpha-synuclein suppresses microglial autophagy and promotes neurodegeneration in a mouse model of Parkinson's disease

C-terminal Truncation Exacerbates the Aggregation and Cytotoxicity of Α-Synuclein: A Vicious Cycle in Parkinson's Disease.

α-synuclein regulates Cyclin D1 to promote abnormal initiation of the cell cycle and induce apoptosis in dopamine neurons